Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: A possible mechanism of the anticachectic effect

British Journal of Cancer

Volumn 79, Issue 3-4, 1999, Pages 631-636

  Kurebayashi, J ^a   Yamamoto, S ^a   Otsuki, T ^a   Sonoo, H ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; Cachexia; Cell line; Interleukin 6; Medroxyprogesterone acetate

Indexed keywords

INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BREAST CANCER; CACHEXIA; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BODY WEIGHT; BREAST NEOPLASMS; CACHEXIA; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-6; MEDROXYPROGESTERONE 17-ACETATE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 0032960563     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690099     Document Type: Article

References (36)

1. Beutler B and Cerani A (1986) Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320: 584-588
2. Billingsley KG, Fraker DL, Strassmann G, Loeser C, Fliot HM and Alexander HR (1996) Macrophage-derived tumor necrosis factor and tumor-derived leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann Surg Oncol 3: 29-35
3. Chiu JJ, Sgagias MK and Cowan KH (1996) Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 2: 215-221
4. De La Mata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR and Roodman GD (1995) Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 95: 2846-2852
5. Downer S, Joel S, Allbright A, Plant H, Stubbs L, Talbot D and Slevin M (1993) A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 67: 1102-1105
6. Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y and Ishistuka H (1995) Establishment and characterization of cancer-inducing and non-inducing clones of murine colon 26 carcinoma. Int J Cancer 61: 522-528
7. Gebbia V, Testa A and Gebbia N (1996) Prospective randomized trial of two doses of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 73: 1576-1580
8. Greenberg SA, Nordan RP, McIntosh J, Calvo JC, Scow RO and Jablons D (1992) Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 52: 4113-4116
9. Kajimura N, Iseki H, Tanaka R, Ohue C, Otsubo K, Gyoutoku M, Sasaki K, Akiyama Y and Yamaguchi K (1996) Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines. Cancer Chemother Pharmacol 38: 48-52
10. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoka H, Tang B, Tanabe O, Tanaka H, Kuramoto A and Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85
11. Kishimoto T (1989) The biology of interleukin 6. Blood 74: 1-10
12. Kurebayashi J, Tang CK, Kurosumi M and Sonoo H (1997) Establishment of a new human breast cancer cell line, KPL-4, overexpressing three members of the Erb B family. Proc Am Assoc Cancer Res 38: 236
13. Kurebayashi J, Tang CK, Otsuki T, Kurosumi M, Yamamoto S, Tanaka K, Mochizuki M, Nakamura H and Sonoo H (1999) Isolation and characterization of new human breast cancer cell line, KPL-4, expressing Erb B family receptors and interleukin-6. Br J Cancer (in press)
14. Matthys P, Dijkmans R, Proost P, Van Damme J, Hermans H, Sobis H and Billiau A (1991) Severe cachexia in mice inoculated with interferon-γ-producing tumor cells. Int J Cancer 49: 77-82
15. Metcalf D, Nicola NA and Gearing DP (1990) Effects of leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76: 50-56
16. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokaya K, Sonoda T, Hirano T and Kishimoto T (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250: 607-610
17. Moldawer LL, Andersson C, Glein J and Lundholm KG (1988) Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol 254: 450-456
18. Montovani G, Maccio A, Esu S, Lai P, Santona MC, Massa E, Dessi D, Melis GB and Del Giacco GS (1997) Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 33: 602-607
19. Mori K, Fujimoto-Ouchi K, Ishikawa T, Sekiguchi F, Ishitsuka H and Tanaka Y (1996) Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 67: 849-855
20. Narita T, Kawakami-Kimura N, Matsuura N, Hosono J and Kannagi R (1995) Corticosteroids and medroxyprogesterone acetate inhibit the induction of E-selectin on the vascular endothelium by MDA-MB-231 breast cancer cells. Anticancer Res 15: 2523-2527
21. Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Miura K, Saito H, Koishihara Y, Ohsugi Y, Oihara T, Nishio K and Saijo N (1993) Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shorten survival in syngenic mice. Br J Cancer 67: 939-944
22. Ohira T, Nishio K, Ohe Y, Arioka H, Nishio M, Funakawa Y, Ogasawara H, Fukuda M, Yazawa K, Kato H and Saijo N (1996) Improvement by cicosanoids in cancer cachexia induced by LCC-IL6 transplantation. J Cancer Res Clin Oncol 122: 711-715
23. Ohsumi J, Miyadai K, Kawasahima I, Sakakibara S, Yamaguchi J and Itoh Y (1994) Regulation of lipoprotein lipase synthesis in 3T3-L1 adipocytes by interleukin-11/adipogenesis inhibitory factor. Biochem Mol Biol Int 32: 705-712
24. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, Hirose K, Ishihara T and Suzuki T (1996) Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56: 2776-2780
25. Okamoto M, Hattori K and Oyasu R (1997a) Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 72: 149-154
26. Okamoto M, Lee C and Oyasu R (1997b) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57: 141-146
27. Poulin R, Baker D, Poirier D and Labrie F (1989) Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 13: 161-172
28. Strassmann G, Fong M, Kenney JS and Jacob CO (1992a) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684
29. Strassmann G, Jacob CO, Evans R, Beall D and Fong M (1992b) Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 148: 3674-3678
30. Takemura M, Kiyoshima M, Saito K, Noma A, Shinoda J, Sato M and Kasai C (1996) Evaluation of interleukin-6 (IL-6) measurement by highly sensitive chemiluminescent enzyme immunoassay (Japanese). Igaku-to-Yakugaku 36: 1071-1076
31. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K and Tisdale M (1996) Characterization of a cancer cachectic factor. Nature 379: 739-742
32. Tominaga T, Abe O, Ohshima A, Hayasaka H, Uchino J, Abe R, Enomoto K, Izuo M, Watanabe H, Takatani O, Yoshida M, Sakai K, Koyama H, Haltori T, Senoo T, Monden Y and Nomura Y (1994) Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer 30: 959-964
33. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki H and Monden M (1996) Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 97: 244-249
34. Van Veelen H, Willemse PH, Tjabbes T and Sleijfer DT (1986) Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 58: 7-13
35. Yamashita J, Hideshima T, Shirakusa T and Ogawa M (1996) Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma. Cancer 78: 2346-2352
36. Yasumoto K, Mukaida N, Harada A, Kuno K, Akiyama M, Nakashima E, Fujioka N, Mai M, Kasahara T, Fujimoto-Ouchi K, Mori K, Tanaka Y and Matsushima K (1995) Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 55: 921-927